Hexacarboxylporphyrin I

Hexacarboxylporphyrin I

HEXA1 SDS

See related porphyria research compounds:

• Uroporphyrin I
• Uroporphyrin III
• Heptacarboxylporphyrin I
• Pentacarboxylporphyrin I

Molecular Formula: C38H38N4O12

CAS#:  N/A

SMILES: CC1=C(CCC(O)=O)/C2=C/C3=C(CC(O)=O)C(CCC(O)=O)=C(N3)/C=C4C(CC(O)=O)=C(CCC(O)=O)C(/C=C5N/C(C(CCC(O)=O)=C\5C)=C\C1=N2)=N/4

MDL#: N/A

Catalog#:  HEXA1 

Molecular weight:  742.74 g/mol 

Other names: 

Fields of Interest: Hexacarboxylporphyrin I is an important analyte used in the diagnosis of porphyria diseases and is a decarboxylation product of Uroporphyrin I. The presence of Hexacarboxylporphyrin I in biological samples indicates a malfunction of the heme biosynthesis pathway.

Background & Applications: Hexacarboxylporphyrin I is an important analyte used in the determination of porphyria diseases.

Appearance: Dark purple solid 

Purity: ≥95% Uroporphyrin, ≥90% Hexacarboxylporphyrin I

Storage: −20 °C

Solubility: Soluble in basic aqueous media (pH >9.5) or in highly acidic media (pH <2). Beware that when dissolved in highly acidic aqueous solutions there may be some degradation of the Hexacarboxylporphyrin I to form decarboxylated byproducts.

Literature: 

Harada, Y.; Murayama, Y.; Takamatsu, T.; Otsuji, E.; Tanaka, H. 5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence Imaging for Tumor Detection: Recent Advances and Challenges. Int. J. Mol. Sci. 2022, 23, 6478. https://doi.org/10.3390/ijms23126478 

Kiening, M.; Lange, N. A Recap of Heme Metabolism towards Understanding Protoporphyrin IX Selectivity in Cancer Cells. Int. J. Mol. Sci. 2022, 23, 7974. https://doi.org/10.3390/ijms23147974 

Di Pierro, E.; De Canio, M.; Mercadante, R.; Savino, M.; Granata, F.; Tavazzi, D.; Nicolli, A.M.; Trevisan, A.; Marchini, S.; Fustinoni, S. Laboratory Diagnosis of Porphyria. Diagnostics 2021, 11, 1343. https://doi.org/10.3390/diagnostics11081343 

Phillips, J. D Heme Biosynthesis and the Porphyrias Molecular Genetics and Metabolism 2019, 3, 164-177. https://doi.org/10.1016/j.ymgme.2019.04.008